30 Days / 30% OFF Holiday Event
BLACK FRIDAY 40% OFF

Enjoy 15% Off Every Order – Use Code: PP-15 at Checkout

Free shipping on all orders over $300

sales@priority-peptides.com
Survodutide 10mg

Survodutide 10mg

$119.99

Out of stock

Survodutide: A Dual GLP-1/Glucagon Receptor Agonist for In Vitro Metabolic and Endocrine Research

What Is Survodutide?

Survodutide (also referred to as BI 456906) is a synthetic, long-acting dual agonist peptide engineered to target glucagon-like peptide-1 (GLP-1) and glucagon (GCGR) receptors. It has been developed to mimic the metabolic effects of native gut hormones, particularly for the management of obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH) through enhanced energy expenditure, appetite suppression, and improved insulin sensitivity.

Co-developed by Boehringer Ingelheim and Zealand Pharma, survodutide is a promising molecule in the incretin mimetic class of peptides and is currently under Phase II clinical investigation for multiple metabolic disorders.

Chemical Information

  • Name: Survodutide (BI 456906)
  • CAS Number: 2805997-46-8
  • Molecular Formula: C232H353N47O70
  • Molecular Weight: ~5312.6 Da
  • Peptide Type: Synthetic dual GLP-1/GCGR agonist
  • Structure: A fatty acid–modified peptide with stabilized conformation and extended half-life through albumin binding.

Amino Acid Sequence & Modifications

The exact sequence of Survodutide is not fully disclosed in public databases due to ongoing proprietary clinical development. However, the molecule is described as a fatty acid–acylated, long-acting peptide analog of oxyntomodulin, incorporating:

  • An amide-modified C-terminus,
  • A C18 fatty diacid side chain, covalently bound to a lysine residue through a linker to facilitate albumin binding and prolong plasma half-life,
  • Amino acid substitutions for DPP-4 resistance and receptor specificity.

These chemical modifications contribute to prolonged receptor engagement, reduced degradation, and selective activation of both GLP-1 and glucagon receptors.

Mechanism of Action

Survodutide acts via simultaneous activation of:

  • GLP-1 receptors, which enhances glucose-dependent insulin secretion, delays gastric emptying, and suppresses appetite.
  • Glucagon receptors, which stimulate lipolysis, increase energy expenditure, and may reduce hepatic steatosis.

The dual action mimics the natural effect of oxyntomodulin, leading to synergistic metabolic outcomes, including improved glycemic control, fat oxidation, and body weight regulation.

Survodutide Research Summary

Preclinical Findings:

  • In rodent models, Survodutide significantly reduced body weight and improved lipid profiles.
  • Dual receptor activation led to greater energy expenditure compared to GLP-1 monoagonists.

Clinical Trials:

  • In a Phase 1b study, Survodutide demonstrated dose-dependent reductions in body weight in people with obesity, without significant safety concerns.
  • Phase 2 trials have shown up to 19% weight loss, with concurrent reductions in liver fat content, supporting its potential in NASH therapy.
  • The peptide continues to be investigated for its anti-obesity, glucose-lowering, and anti-inflammatory effects in metabolic syndrome contexts.

Potential Areas for Future Research

Survodutide opens new avenues for exploring:

  • Mechanistic dissection of GLP-1 vs. GCGR synergy in hepatic lipid metabolism,
  • Adipose tissue remodeling and thermogenesis,
  • Neuroendocrine appetite signaling pathways,
  • Effects on cardiovascular risk markers,
  • Comparative studies with tirzepatide and mazdutide (other dual and triple agonists).

Key Citations & Resources

  1. Jastreboff, A.M. et al. “Survodutide, a dual GLP-1/glucagon receptor agonist, in adults with overweight or obesity: A phase 2 trial.” NEJM (2023).

 https://www.nejm.org/doi/full/10.1056/NEJMoa2301993

  1. Zealand Pharma & Boehringer Ingelheim – Clinical Trial Listing:

 https://clinicaltrials.gov/ct2/show/NCT04667377

  1. Coskun, T. et al. “Mechanisms of action of dual GLP-1/glucagon receptor agonists.” Cell Metabolism (2018).

 https://doi.org/10.1016/j.cmet.2018.07.011

Disclaimer

This product is intended for research purposes only. It is not approved for human or veterinary use, nor is it intended for clinical, diagnostic, or therapeutic applications. All research must comply with applicable local laws and institutional guidelines. Misuse of this compound for human consumption is strictly prohibited.

Scroll to Top

Legal Disclaimer

All products offered by Priority-Peptides are strictly intended for laboratory research use only. These compounds are not for human or animal consumption, nor are they approved for therapeutic, diagnostic, or clinical applications. They are intended exclusively for in vitro studies or laboratory-based experimentation by qualified professionals.
 
By purchasing from Priority-Peptides, you affirm that:
 
You are at least 21 years of age.
 
You are a qualified researcher, scientist, or licensed professional.
 
You will use all products in accordance with applicable federal, state, and local laws and regulations.
 
Priority-Peptides does not condone or promote the misuse of any research chemical or compound. Products are offered with the understanding that they are not medications, dietary supplements, or consumer products, and are not intended to diagnose, treat, cure, or prevent any disease.
 
Restricted Substances Notice:
Certain products may be regulated or restricted under state or federal law (e.g., controlled substances, prescription analogs). It is the buyer’s responsibility to understand and comply with all applicable regulations before ordering. We reserve the right to refuse sale to any individual or entity if misuse is suspected.
  
Priority-Peptides assumes no liability for any damages or injuries resulting from the use, misuse, or handling of any product sold. All customers are responsible for the safe storage, handling, and disposal of all materials.
 
By placing an order, you confirm that you have read, understood, and agreed to these terms.
I agree to these terms.
I do not agree